Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study

1. Reitz C, Brayne C, Mayeux R Epidemiology of Alzheimer disease. Nature Reviews Neurology.2011; 7: 137–152. doi: 10.1038/nrneurol.2011.2 21304480

2. http://www.alz.org/what-is-dementia.asp.

3. Alzheimer's Disease International: World Alzheimer's report 2015, the global impact of dementia: an analysis of prevalence, incidence, cost and trends. 2015.

4. de la Monte SM, Tong M Brain metabolic dysfunction at the core of Alzheimer's disease. Biochemical Pharmacology.2014; 88: 548–559. doi: 10.1016/j.bcp.2013.12.012 24380887

5. Snowden S, Dahlén S-E, Wheelock CE Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis.2012; 4: 2265–2290. doi: 10.4155/bio.12.218 23046268

6. Fiehn O (2002) Metabolomics—the link between genotypes and phenotypes. In: Town C, editor. Functional Genomics: Springer Netherlands. pp. 155–171.

7. Ebshiana AA, Snowden SG, Thambisetty M, Parsons R, Hye A, et al. Metabolomic Method: UPLC-q-ToF Polar and Non-Polar Metabolites in the Healthy Rat Cerebellum Using an In-Vial Dual Extraction. PLoS ONE.2015; 10: e0122883. doi: 10.1371/journal.pone.0122883 25853858

8. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. ELECTROPHORESIS.2009; 30: 1235–1239. doi: 10.1002/elps.200800589 19288586

9. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, et al. Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics. PLoS ONE.2011; 6: e21643. doi: 10.1371/journal.pone.0021643 21779331

10. Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimer's & Dementia.2011; 7: 309–317.

11. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, et al. Metabolome in progression to Alzheimer's disease. Transl Psychiatry.2011; 1: e57. doi: 10.1038/tp.2011.55 22832349

12. Whiley L, Sen A, Heaton J, Proitsi P, García-Gómez D, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging.2014; 35: 271–278. doi: 10.1016/j.neurobiolaging.2013.08.001 24041970

13. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med.2014; 20: 415–418. doi: 10.1038/nm.3466 24608097

14. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochemistry International.2010; 56: 937–947. doi: 10.1016/j.neuint.2010.04.001 20398713

15. Graham SF, Chevallier OP, Roberts D, Hölscher C, Elliott CT, et al. Investigation of the Human Brain Metabolome to Identify Potential Markers for Early Diagnosis and Therapeutic Targets of Alzheimer’s Disease. Analytical Chemistry.2013; 85: 1803–1811. doi: 10.1021/ac303163f 23252551

16. Inoue K, Tsutsui H, Akatsu H, Hashizume Y, Matsukawa N, et al. Metabolic profiling of Alzheimer's disease brains. Scientific Reports.2013; 3: 2364. doi: 10.1038/srep02364 23917584

17. Braak H, Braak E Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease. Neurobiology of Aging.1997; 18: S85–S88. 9330992

18. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer’s disease: a critical update. In: Gertz HJ, Arendt T, editors. Alzheimer’s Disease—From Basic Research to Clinical Applications. Vienna: Springer Vienna. pp. 77–95.

19. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology.2006; 66: 1837–1844. doi: 10.1212/01.wnl.0000219668.47116.e6 16801647

20. Iacono D, Resnick SM, O'Brien R, Zonderman AB, An Y, et al. Mild Cognitive Impairment and Asymptomatic Alzheimer Disease Subjects: Equivalent β-Amyloid and Tau Loads With Divergent Cognitive Outcomes. Journal of Neuropathology & Experimental Neurology.2014; 73: 295–304.

21. Larner AJ The Cerebellum in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders.1997; 8: 203–209. 9213064

22. Shock NW, Gruelich R, Andres R, Arenberg D, Costa PT, et al. Normal human aging. The Baltimore Longitudinal Study of Aging Washington DC. US Government Printing Office.1984.

23. Ferrucci L The Baltimore Longitudinal Study of Aging (BLSA): A 50-Year-Long Journey and Plans for the Future. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.2008; 63: 1416–1419.

24. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology.2000; 54: 2072–2077. 10851365

25. American Psychiatric Association. American Psychiatric Association APAWGtRDSM, III. Diagnostic and statistical manual of mental disorders. 1987.

26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology.1984; 34: 939. 6610841

27. O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, et al. Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA). Journal of Alzheimer's disease: JAD.2009; 18: 665–675. doi: 10.3233/JAD-2009-1179 19661626

28. Gamaldo A, Moghekar A, Kilada S, Resnick SM, Zonderman AB, et al. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology.2006; 67: 1363–1369. doi: 10.1212/01.wnl.0000240285.89067.3f 17060561

29. Kanehisa M, Goto S KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research.2000; 28: 27–30. 10592173

30. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz David H, et al. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. Neuron.2012; 73: 685–697. doi: 10.1016/j.neuron.2011.11.033 22365544

31. Hardy JA, Higgins GA Alzheimer's Disease: The Amyloid Cascade Hypothesis. Science.1992; 256: 184. 1566067

32. Iqbal K, del C. Alonso A, Chen S, Chohan MO, El-Akkad E, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease.2005; 1739: 198–210.

33. Whiley L, Godzien J, Ruperez FJ, Legido-Quigley C, Barbas C In-Vial Dual Extraction for Direct LC-MS Analysis of Plasma for Comprehensive and Highly Reproducible Metabolic Fingerprinting. Analytical Chemistry.2012; 84: 5992–5999. doi: 10.1021/ac300716u 22702345

34. Xu J, Begley P, Church SJ, Patassini S, Hollywood KA, et al. Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease.2016.

35. Nasaruddin ML, Hölscher C, Kehoe P, Graham SF, Green BD Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer’s disease as detected by GC-MS. American Journal of Translational Research.2016; 8: 154–165. 27069549

36. Cunnane SC, Schneider JA, Christine T, Tremblay-Mercier J, Fortier M, et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's disease: JAD.2012; 29: 691–697. doi: 10.3233/JAD-2012-110629 22466064

37. Amtul Z, Uhrig M, Wang L, Rozmahel RF, Beyreuther K Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. Neurobiology of Aging.2012; 33: 831.e821–831.e831.

38. Wilson DM, Binder LI Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. The American Journal of Pathology.1997; 150: 2181–2195. 9176408

39. Amtul Z, Westaway D, Cechetto DF, Rozmahel RF Oleic Acid Ameliorates Amyloidosis in Cellular and Mouse Models of Alzheimer's Disease. Brain Pathology.2011; 21: 321–329. doi: 10.1111/j.1750-3639.2010.00449.x 21040071

40. Park Y-S, Jang H-J, Lee K-H, Hahn T-R, Paik Y-S Prolyl Endopeptidase Inhibitory Activity of Unsaturated Fatty Acids. Journal of Agricultural and Food Chemistry.2006; 54: 1238–1242. doi: 10.1021/jf052521h 16478242

41. López-Miranda J, Pérez-Jiménez F, Ros E, De Caterina R, Badimón L, et al. Olive oil and health: Summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008. Nutrition, Metabolism and Cardiovascular Diseases.2010; 20: 284–294. doi: 10.1016/j.numecd.2009.12.007 20303720

42. Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: A randomized clinical trial. JAMA Internal Medicine.2015; 175: 1094–1103. doi: 10.1001/jamainternmed.2015.1668 25961184

43. Pelletier A, Barul C, Féart C, Helmer C, Bernard C, et al. Mediterranean diet and preserved brain structural connectivity in older subjects. Alzheimer's & Dementia.2015; 11: 1023–1031.

44. Martinez-Lapiscina EH, Clavero P, Toledo E, San Julian B, Sanchez-Tainta A, et al. Virgin olive oil supplementation and long-term cognition: the Predimed-Navarra randomized, trial. The journal of nutrition, health & aging.2013; 17: 544–552.

45. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. Journal of Neurochemistry.2002; 81: 1084–1091. 12065621

46. Cole GM, Frautschy SA Docosahexaenoic Acid Protects from Amyloid and Dendritic Pathology in an Alzheimer's Disease Mouse Model. Nutrition and Health.2006; 18: 249–259. doi: 10.1177/026010600601800307 17180870

47. Cole GM, Frautschy SA DHA May Prevent Age-Related Dementia. The Journal of Nutrition.2010; 140: 869–874. doi: 10.3945/jn.109.113910 20181786

48. Swanson D, Block R, Mousa SA Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Advances in Nutrition: An International Review Journal.2012; 3: 1–7.

49. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Ω-3 fatty acid treatment in 174 patients with mild to moderate alzheimer disease: Omegad study: a randomized double-blind trial. Archives of Neurology.2006; 63: 1402–1408. doi: 10.1001/archneur.63.10.1402 17030655

50. Morris M, Evans DA, Bienias JL, et al. COnsumption of fish and n-3 fatty acids and risk of incident alzheimer disease. Archives of Neurology.2003; 60: 940–946. doi: 10.1001/archneur.60.7.940 12873849

51. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in alzheimer disease: A randomized trial. JAMA.2010; 304: 1903–1911. doi: 10.1001/jama.2010.1510 21045096

52. Grimm MOW, Kuchenbecker J, Grösgen S, Burg VK, Hundsdörfer B, et al. Docosahexaenoic Acid Reduces Amyloid β Production via Multiple Pleiotropic Mechanisms. Journal of Biological Chemistry.2011; 286: 14028–14039. doi: 10.1074/jbc.M110.182329 21324907

53. James MJ, Gibson RA, Cleland LG Dietary polyunsaturated fatty acids and inflammatory mediator production. The American Journal of Clinical Nutrition.2000; 71: 343s–348s. 10617994

54. Rola-Pleszczynski M, Thivierge M, Gagnon N, Lacasse C, Stankova J Differential regulation of cytokine and cytokine receptor genes by PAF, LTB4 and PGE2. Journal of lipid mediators.1993; 6: 175–181. 8395242

55. Hawkes JS, James MJ, Cleland LG Biological activity of prostaglandin E3 with regard to oedema formation in mice. Agents and Actions.1992; 35: 85–87. 1509981

56. Goldman DW, Pickett WC, Goetzl EJ Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochemical and Biophysical Research Communications.1983; 117: 282–288. 6318749

57. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and alzheimer disease: The framingham heart study. Archives of Neurology.2006; 63: 1545–1550. doi: 10.1001/archneur.63.11.1545 17101822

58. Simpson BN, Kim M, Chuang Y-F, Beason-Held L, Kitner-Triolo M, et al. Blood metabolite markers of cognitive performance and brain function in aging. Journal of Cerebral Blood Flow & Metabolism.2015.

59. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, DeKosky ST Increased 5-Lipoxygenase Immunoreactivity in the Hippocampus of Patients With Alzheimer's Disease. Journal of Histochemistry & Cytochemistry.2008; 56: 1065–1073.

60. Manev H 5-Lipoxygenase gene polymorphism and onset of Alzheimer's disease. Medical Hypotheses.2000; 54: 75–76. doi: 10.1054/mehy.1998.0824 10790729

61. Bazan NG, Colangelo V, Lukiw WJ Prostaglandins and other lipid mediators in Alzheimer’s disease. Prostaglandins & Other Lipid Mediators.2002; 68–69: 197–210.

62. Funk CD Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology. Science.2001; 294: 1871–1875. doi: 10.1126/science.294.5548.1871 11729303

63. Sanchez-Mejia RO, Newman JW, Toh S, Yu G-Q, Zhou Y, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci.2008; 11: 1311–1318. doi: 10.1038/nn.2213 18931664

64. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of Experimental Medicine.2009; 206: 15–23. doi: 10.1084/jem.20081880 19103881

65. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, et al. Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals. The Journal of Experimental Medicine.2002; 196: 1025–1037. doi: 10.1084/jem.20020760 12391014

66. Ariel A, Serhan CN Resolvins and protectins in the termination program of acute inflammation. Trends in Immunology.2007; 28: 176–183. doi: 10.1016/j.it.2007.02.007 17337246

67. Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, et al. 1α,25-Dihydroxyvitamin D(3) and Resolvin D1 Retune the Balance between Amyloid-β Phagocytosis and Inflammation in Alzheimer’s Disease Patients. Journal of Alzheimer's disease: JAD.2013; 34: 155–170. doi: 10.3233/JAD-121735 23186989

68. Farooqui AA Lipid mediators and their metabolism in the nucleous: implications for Alzheimer's disease. Journal of Alzheimer's disease: JAD.2012; 30 Suppl 2: S163–178.